Market Research Industry Reports

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition thats triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 4, 18, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Post-Traumatic Stress Disorder (PTSD) - Overview 6
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development 7
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 15
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 23
Post-Traumatic Stress Disorder (PTSD) - Drug Profiles 32
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 112
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 115
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 116
Appendix 124

List Of Tables

List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2018
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2018, provides an overview

USD 2000View Report

Post-Traumatic Stress Disorder (PTSD) - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Post-Traumatic Stress Disorder (PTSD) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Post-Traumatic Stress Disorder (PTSD) epidemiology and market

USD 6250View Report

Post-Traumatic Stress Disorder (PTSD) - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Post-Traumatic Stress Disorder (PTSD) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Post-Traumatic Stress Disorder (PTSD) epidemiology and market

USD 6250View Report

Post-Traumatic Stress Disorder (PTSD) - Epidemiology Forecast to 2027

DelveInsights Post-Traumatic Stress Disorder (PTSD) - Epidemiology Forecast, 2027 report provides a comprehensive analysis of the Post-Traumatic Stress Disorder (PTSD) epidemiology, providing the historical and forecasted

USD 3250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF USD 2000    USD 1600
  • Site Licence USD 4000    USD 3200
  • Enterprise Wide Licence USD 6000    USD 4800
$ 1600

Reports Details

Published Date : Jul 2018
No. of Pages :129
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube